Lund, Sweden — November 14, 2025 — TFS HealthScience (TFS), a leading global Contract Research Organization (CRO), continues to expand its footprint in neuroscience clinical research, marking another milestone in advancing the treatment of neurodegenerative diseases. Building on the expanding scope of international collaborations, our Neuroscience business unit is expanding its gene therapy portfolio across multiple indications, including Alzheimer’s disease, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, and acute flaccid myelitis.
This momentum reflects our deep expertise in advanced therapeutic modalities (ATMPs) and our commitment to shaping the future of neuroscience through innovation and collaboration.
Global Reach, Unified Vision
With expanding projects globally across Western and Central Europe, the United States, Canada, and Australia, TFS continues to accelerate progress as a trusted partner in neuroscience research worldwide. Our teams deliver scientific expertise, operational flexibility, and transparent communication at every stage of clinical development, empowering sponsors to bring new therapies to market more quickly and confidently.
Expert Voices
“This milestone reinforces our position as a trusted partner in neurodegenerative and gene therapy studies,” said Anne-Marie Nagy, PhD, VP, Head of Internal Medicine & Neuroscience. “It highlights the strength of our cross-functional expertise and the dedication of our teams across TFS to advancing science that can change lives.”
“Having spent nearly two decades in neurodegenerative clinical development, I can finally see a light at the end of the tunnel,” added Sebastian Turek, Executive Director, Internal Medicine & Neuroscience. “Our progress in this space reflects the trust built with our partners and our shared mission to bring hope to patients and families affected by neurodegenerative diseases.”
Moving Science Forward Together
Every step forward in neuroscience research brings us closer to transforming the course of neurodegenerative diseases and improving outcomes for patients worldwide. At TFS, we are proud to contribute to that journey, proving that partnership truly fuels progress.
About TFS HealthScience
TFS HealthScience is a full-service, global Contract Research Organization (CRO) that partners with biotechnology and pharmaceutical companies to advance innovative treatments and improve patient outcomes. With operations across 50 countries, TFS and its strategic partners provide tailored strategic resourcing solutions and clinical development services in specialized therapeutic areas, including dermatology, internal medicine, neuroscience, oncology, and ophthalmology. Dedicated to empowering partners and enriching lives, TFS offers flexible solutions that combine global reach with the agility and responsiveness of a mid-sized CRO.
For more information, visit www.tfscro.com.